Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

A parenting expert has given five top tips to help parents adjust to a quieter household as millions of students prepare to ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

Some better-ranked stocks in the broader medical space are TransMedix Group TMDX, Veracyte VCYT and Boston Scientific BSX. While TransMedix Group and Veracyte currently sport a Zacks Rank #1 (Strong ...

The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets.

t:slim X2 became the first automated insulin delivery (AID) system to integrate with Abbott’s new FreeStyle Libre 2 Plus sensor in 2023. The breakthrough development has enabled t:slim X2 users ...

The t:slim X2 pump is currently cleared for use with Humalog and Novolog/NovoRapid U-100 insulins globally, and Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi U-100 insulins in Canada ...

Most recently, Dexcom this week launched its first over-the-counter CGM, the Stelo, aimed at offering a more “health-focused” sensor ... The Libre Rio is designed for adults with Type 2 ...

Both of Abbott's over-the-counter CGMS are based on its popular FreeStyle Libre sensor technology ... It was designed for people with Type 2 diabetes and prediabetes in mind, so they can see ...